Research Study

Past Study: A9001498

Study Status: CLOSED

Study Name:  A9001498      

Study Focus:  Obesity


Study Contact: To learn more, please call 1-877-854-8475 or fill out the Contact us form.

Study Purpose:  The purpose of this research study is to assess the effect of Liraglutide or placebo administration on food intake in obese subjects.  Liraglutide is a medication that is FDA approved for the treatment of obesity.  

To be enrolled in this study, you must meet certain requirements. You may be eligible to participate if you meet the following criteria:

  • Healthy, non-diabetic men and women
  • Age 18-75 years, inclusive
  • BMI of 30.0 to 40.0 kg/m2

Study Duration: up to 14 weeks (maximum)

Study Procedures:

  •  Physical exam, height, weight, vital signs, EKG, medical history and current medication
  • Blood and urine collections
  • Dual Energy X-ray Absorptiometry (DEXA) to measure body composition
  • Study Drug administration

Study Commitment:

  •  1 Screening visit
  • Total of 6 visits, including 3 outpatient visits and 3 inpatients visits, each inpatient stay consists of 4 days and 3 nights.  Participants will continue to have daily dosing done at the clinic or at their home between visits 3 and 4 and visits 4 and 5. All visits are completed at The Translational Research Institute for Metabolism and Diabetes (TRI-MD).
  • Between the visits mentioned above, daily dosing (either at your home or by traveling into TRI-MD) will occur for a total of approximately 36 days   
  • In addition, there will be follow up contact via phone call, within 28 to 34 days after last dose of the study product.

Compensation offered: up to $4800.00.

This study is being conducted under the direction of Steven Smith, MD at 301 East Princeton Street, Orlando, Florida 32804.